Floatz logo

Favezelimab

Esophageal Squamous Cell Carcinoma (ESCC)

Merck Sharp & Dohme LLCmonoclonal_antibodyPhase 1/2Active
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

64 Active assets in the Esophageal Squamous Cell Carcinoma (ESCC) cohort.

Asset / SponsorPhaseRating
Eloxatin
Taiho Oncology, Inc.
Phase 3BB
FLUOROURACILUM
AstraZeneca
Phase 3BB
Irinotecan
Taiho Oncology, Inc.
Phase 2BB
Levoleucovorin
Taiho Oncology, Inc.
Phase 3BB
Cetuximab
Hummingbird Bioscience
Phase 2B

View all 50 →

Same molecule, other indications

Favezelimab is also rated in:

Hodgkins lymphomaDormant
BB
Indicative ·
67 / 100
View asset →
colorectal cancerDormant
B
Indicative ·
60 / 100
View asset →
neoplasmDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →